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ABSTRACT 
Objectives: To investigate the feasibility and cost-effectiveness of a de novo, ECG-based 
cardiac screening programme of elite rugby players. 
Design: Prospective, cohort study. 
Participants: 1191 rugby players aged ≥16 years who were selected for the England teams 
or registered with the regional academies and Premiership clubs who underwent cardiac 
screening between 2010 and 2012. 
Setting: Screening of young competitive athletes for conditions predisposing to sudden 
cardiac death (SCD) remains a contentious issue, primarily due to concerns relating to the 
false positive rate of the 12-lead ECG and the cost of subsequent investigations. In 2010 the 
Rugby Football Union (RFU), Premiership Rugby and the Rugby Players Association made an 
executive decision to offer cardiac screening to all professional and aspiring professional 
players in England. The cardiac screening included a health questionnaire, a 12-lead ECG and 
a cardiology consultation. Players with concerning findings on initial evaluation were offered 
on-site transthoracic echocardiogram (TTE). Athletes were referred for further 
investigations as deemed necessary. The overall cost of the screening program was 
estimated. 
Results: After initial evaluation 9.7% of athletes underwent on-site TTE: 8.2% due to ECG 
anomalies and 1.4% due to concerns on the questionnaire. After TTE, only 2.9% of the 
players were referred for further evaluation. Two players were considered to harbour 
potentially serious conditions, of which 1 exhibited the Wolff-Parkinson-White phenotype 
and resumed competition after catheter ablation and the other was diagnosed with 
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hypertrophic cardiomyopathy and withdrew from competition. During a mean follow-up of 
52.8±5.5 months, none of the players who were cleared experienced any adverse cardiac 
events. The total cost of the screening programme was £59875, which averaged to a cost of 
£50 per player or £29,938 per condition identified. The application of the latest refined ECG 
criteria would have reduced the ECG false positive rate to < 5%. 
Conclusion: Preparticipation cardiovascular screening with 12-lead ECG is feasible. 
Refinement of the ECG criteria, the utility of on-site TTE and expert setting ensure a low 
false positive rate, minimise the burden of unnecessary investigations and reduce costs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
INTRODUCTION 
 
Sudden cardiac death (SCD) is one of the leading causes of death in young (≤35 years) 
athletes. The majority of deaths are attributed to inherited or congenital cardiac disorders,1 
some of which can be detected during life. A mandatory, ECG-based, pre-participation 
cardiovascular screening (PPS) program in the Veneto region of Italy reported a reduction in 
the incidence of SCD in young athletes through the early identification of 
cardiomyopathies.2 Based on these results, a number of International sporting and scientific 
organisations advocate cardiac screening of young competitive athletes for the prevention 
of such tragedies.3 Intense debate, however, remains over the feasibility of such an 
endeavour, relating primarily to the potential large number of false positive tests and the 
associated costs. In the current era, where national health systems are strapped of financial 
resources, a large number of specialist investigations aiming to reassure athletes with an 
abnormal ECG are likely to be cost-prohibitive. In an attempt to improve the ECG’s 
specificity the ESC and other expert consortiums have revised the original 2005 ESC criteria 
relating to which ECG changes should raise suspicion of underlying heart disease.4,5 
Preliminary studies suggest that adoption of more refined ECG criteria results in a significant 
reduction of the false positive rates.6,7 
 
In the United Kingdom there is no state-sponsored cardiac screening program. In 2010, the 
Rugby Football Union (RFU), Premiership Rugby and the Rugby Players Association 
introduced a nationwide, voluntary, cardiac screening for all eligible rugby players ≥16 years 
of age. This provided a unique opportunity to assess the feasibility and cost-effectiveness of 
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an ECG-based cardiac screening programme in a real life model. In addition this study offers 
a unique perspective as it describes ECG characteristics in a group of elite, male athletes 
typically with a high body mass, competing in a single discipline. We also compared the 
performance of newly proposed criteria to those currently recommended by the ESC.4,5,8 
 
METHODS 
 
Setting: 
In 1995 the charitable organisation Cardiac Risk in the Young (CRY) established a cardiac 
screening program, aimed at young (14-35 years) individuals at risk of SCD. Screening is 
offered to any young individual, athlete and non-athlete, who wish to be screened for self-
protection. Through its mobile units, CRY is able to offer screening throughout the UK. 
 
Cardiac screening of elite rugby players selected to represent England has been in place 
since 2005, in an attempt to identify those with quiescent cardiac disease and safeguard 
their safety. The small but constant trickle of SCDs in young sportsmen, led the Rugby 
Football Union, Premiership Rugby and the Rugby Players Association to expand the existing 
programme. Since 2010, cardiac screening is offered to all players aged ≥16 years who 
represent England and those playing at the highest level of domestic competition, including 
players registered with the Premiership clubs (n=12) and the Regional Academies. The 
cardiac screening events required the co-ordinated efforts of respective team 
 8 
administrators and medical staff and CRY in identifying the athletes eligible for screening, 
planning and implementing the screening, delivering the results and arranging appropriate 
follow-up. All screenings were conducted by CRY. The CRY screening team consisted of a 
screening manager, a team of accredited cardiac physiologists and a cardiology fellow with 
experience in sports cardiology and inherited cardiac diseases. The cardiac screening 
included a detailed health questionnaire, a 12-lead ECG and a consultation with the 
cardiologist. On-site transthoracic echocardiogram (TTE) was performed on individuals who 
exhibited an abnormality during the initial evaluation. Athletes were referred for further 
comprehensive evaluation or regular follow-up, as deemed necessary. 
 
Participants 
Between January 2010 and December 2012, 1191 male rugby players (aged 14 – 37 years; 6 
players aged >35 years) underwent PPS. The health questionnaires, including a consent 
form, were distributed to the players prior to the screening. Questions related to the 
presence of cardiac symptoms, such as syncope, dizziness, chest pain, palpitations and 
shortness of breath, family history of inherited cardiac disease or premature SCD (≤40 years) 
and drug history. In addition, data regarding height, weight, ethnicity, and training level and 
duration were collected. 
 
12-lead electrocardiography: 
A standard 12-lead ECG was performed during quiet respiration at rest in all athletes using a 
Philips Pagewriter Trim III (Bothel, WA, USA) machine with a paper speed of 25mm/s and 
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amplification of 0.1mV/mm. The ECG was performed in a supine position and electrodes 
were placed carefully to ensure consistency of precordial lead positions. The ECG trace was 
stored electronically. The ECG findings were classified as ‘Group 1’ or ‘training-related’ and 
‘Group 2’ or ‘training-unrelated’ changes similar to the ESC 2010 recommendations.4 The 
resting heart rate, PR interval, QRS axis, QRS duration, QT interval, voltage of QRS complex, 
T-wave abnormalities and ST-segment changes were recorded. The QT interval was 
corrected for heart rate (QTc) using Bazett’s formula. Left ventricular hypertrophy (LVH) was 
determined by the Sokolow-Lyon voltage criterion (LVH: S-V1 + R-V5/V6 = >3.5mV). Early 
repolarization (ER) was defined by J-point elevation of ≥1mm in ≥2 continuous leads 
(anterior, inferior or lateral); and ER in inferior and lateral leads was further characterised 
based on morphology of QRS complex (notched or slurred) and ST-segment (ascending or 
descending/horizontal). Table 1 outlines the definitions of all ECG changes that required 
further evaluation and provides a comparison with the 2010 ESC and “Seattle” criteria. 
 
Trans-thoracic echocardiogram: 
Two-dimensional trans-thoracic echocardiogram (TTE) was performed by an accredited 
cardiologist or a senior cardiac physiologist. A Philips iE33 or Philips CX50 machine with 3 
MHz transducer were used. Standard views were obtained and chamber and wall thickness 
measurements were performed as per current guidelines.9 The continuous- and pulsed-
Doppler, as well as colour tissue-Doppler imagines were acquired using standard views. 10 
 
Further Evaluation and Follow-up 
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Athletes with personal or family history, ECG or echocardiographic anomalies highly 
suggestive of underlying cardiac pathology were invited for further clinical evaluation. All 
further evaluations were performed after referral by the relevant player’s family physician 
to a specialist cardiac centre via the National Health Service (NHS). Evaluations were 
dictated by the local protocols of the relevant specialist centre and included upright exercise 
stress testing ± cardiopulmonary testing, 24-48 hour Holter, and cardiac magnetic resonance 
imaging with gadolinium injection to check for the broader phenotypic manifestations of 
underlying cardiac disease. Athletes with phenotypes outside the conventional limits but 
considered most likely to represent cardiac adaptation to exercise were invited to repeat 
cardiac evaluations on an annual or two-yearly basis. 
 
Cost analysis: 
The cost of the initial cardiac screening, including: questionnaire, 12-lead ECG, consultation 
and possible on-site ECHO, was set at £35 per athlete. This rate is based on the subsidised 
rate charged by CRY for every young individual (14-35 years) in the UK who wishes to be 
screened. The additional costs of the screening programme are funded by the charity’s 
fundraising activities and voluntary work by participating individuals. Costs resulting from 
referral to specialist centres and further diagnostic tests were derived from the NHS 
payment-by-result tariff 2012-2013; and are expressed in GBP (£). 
 
Ethical Approval/Consent 
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Ethical approval was granted by the National Research Ethics Service, Essex 2 Research 
Ethics Committee. Written consent was obtained from individuals aged 16 years and from 
a parent/guardian for those aged <16 years. 
 
Statistical analysis: 
Data manipulation and analysis were performed using SPSS software, version 20 (Chicago, 
IL, USA). Variables were tested for normality using the Kolmogorov-Smirnov test. Values 
were expressed as mean ± standard deviation (SD) or percentages, as appropriate. 
 
RESULTS 
 
Clinical characteristics: 
Detailed demographics of the rugby players are reported in table 2. The mean body surface 
area of the cohort was 2.25 ± 0.2 m2 reflecting the large body habitus of the athletes. 
Consistent with their professional status, the athletes exercised for an average of 17.2 ± 5.4 
hours per week. 
 
Health questionnaire: 
A significant proportion of athletes (n=179; 15%) reported one or more symptoms in their 
health questionnaire including: dizziness (n=101; 8.5%), chest pain or tightness (n=71; 5.9%), 
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syncope (n=48; 4%), palpitations (n=47; 3.9%) and shortness of breath (n=31; 2.6%). Only 18 
athletes (1.5%) reported symptoms related to exertion. After consultation with the 
cardiologist, only 6 (0.5%) athletes were considered to exhibit clinically significant symptoms 
requiring further evaluation. Ten (0.8%) athletes reported a history of premature SCD or an 
inherited cardiac disease. One athlete had a history of dilated aortic root based on previous 
screening. Thirty-six (3%) athletes reported a history of asthma. 
 
12-lead Electrocardiogram: 
Group 1 ECG changes were detected in 691 (58%) athletes, whereas 107 (9%) athletes 
exhibited at least one group 2 change (Figure 1). The most common group 1 changes 
included the early repolarization (ER) pattern (48.2%), sinus bradycardia (42.6%) and voltage 
criterion for LVH (22.9%) (Table 3). The ER pattern was confined to inferior and/or lateral 
leads in 20.5% athletes and comprised predominantly of a notched QRS (70.2%) with an 
associated ascending ST-segment (82%). A slurred QRS with associated descending or 
horizontal ST-segment confined in the inferior leads was present in 6.6% of rugby players. 
 
The most prevalent group 2 ECG anomaly was the presence of T-wave inversions, which was 
present in 42 (3.5%) athletes. Of the T-wave inversions, 12 (1%) were confined in the 
anterior leads (V1-V4), but only 4 (0.3%) extended beyond lead V2 and overlapped with the 
arrhythmogenic right ventricular cardiomyopathy (ARVC) phenotype. In 27 (2.3%) athletes 
the inferior leads were involved (II, III, aVF), and 3 (0.25%) athletes exhibited T-wave 
inversion extending in the lateral leads (I, aVL, V5-V6). Bundle branch block was rare (0.7%), 
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with RBBB being the predominant pattern. Pathological Q-waves were present in only 1 
athlete, while ST-segment depression was not identified in any athlete. Patterns considered 
to represent softer ECG indicators of underlying heart disease such as voltage criterion for 
axis deviation, atrial enlargement and RVH were present in 3.7%, 1.1% and 1% of athletes, 
respectively (Table 2). A prolonged QTc (>470ms) was seen in 3 (0.25%) athletes, none of 
who had symptoms or relevant family history of note. One athlete had pre-excitation on his 
ECG suggestive of an accessory pathway. 
 
Echocardiographic findings: 
After initial evaluation, 115 athletes underwent on-site TTE; 98 (8.2%) as a result of a Group 
2 anomaly on the ECG and 17 (1.4%) due to concerning findings in the questionnaire (Figure 
2). The attending physician considered that on-site TTE was not essential in nine individuals 
with borderline voltage criteria for axis deviation, RVH and RBBB, in the absence of 
symptoms or family history of note. Three athletes had absolute LVEDD of >65mm (69mm, 
70mm and 72mm) and only 2 athletes had an absolute LV wall thickness of >12mm (13mm 
and 14mm). None of the athletes, however, demonstrated associated echocardiographic 
features suggestive of cardiomyopathy. Other minor cardiac abnormalities detected on TTE 
included 1 bicuspid aortic valve, 1 mild mitral regurgitation, 1 mild pulmonary stenosis, 1 
mildly dilated aortic root (44mm) and 1 patent ductus arteriosus. 
 
Further diagnostic evaluation and follow-up: 
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Of the 115 athletes requiring TTE: 81 (70%) were cleared after a normal scan; 8 players (5 
with minor cardiac abnormalities and 3 with absolute LVEDD of >65mm) were referred for 
surveillance TTE, organised during the time of future screenings; and 26 players were 
referred for further comprehensive evaluation. Further diagnostic evaluation included 
cardiac magnetic resonance imaging (CMR) (n=13), exercise treadmill/cardiopulmonary test 
(ETT) (n=18) and 24-hour ECG monitoring (n=20). Two athletes were diagnosed with a 
condition predisposing to exercise related SCD. An athlete with the Wolf-Parkinson-White 
phenotype (Figure 3A) was referred for an electrophysiological study and underwent 
radiofrequency catheter ablation of the accessory pathway. Following successful recovery 
he returned to competition. One athlete with T-wave inversion extending to the lateral 
leads (Figure 3B) but normal TTE indices at initial screening (maximal wall thickness of 
11mm, LVEDd of 58mm, LA of 43mm, normal systolic & diastolic indices) was diagnosed 
with hypertrophic cardiomyopathy (HCM) during subsequent evaluation and follow-up. 
 
Another athlete with T-wave inversions in anterior and lateral leads (I, aVL, V2-V4) did not 
demonstrate any abnormality on extensive evaluation. He was offered re-evaluation after a 
period of de-training, and this resulted in resolution of ECG changes. He continues to 
compete but remains under follow-up on an annual basis. One player exhibited a small PDA 
with little hemodynamic significance and was asymptomatic; therefore as per Bethesda and 
ESC recommendations, he was allowed to compete in professional sports with repeat TTE 
every 2 years. Those with dilated LV cavity underwent surveillance TTE which did not show 
any significant change; their LV dimensions were deemed acceptable when indexed to body 
surface area, and other echocardiographic parameters including systolic and diastolic 
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functions were normal. The remaining players with minor valve abnormalities undergo 
annual or 2-yearly TTE and continue to play professional rugby. 
 
The 3 athletes with prolonged QTc underwent Holter monitor and exercise stress testing. 
They did not demonstrate any features to suggest underlying long QT syndrome and were 
therefore allowed to compete. 
 
During a mean follow-up period of 52.8 ± 5.5 months, none of the players who were cleared 
after ECG have experienced any adverse cardiac events. Three players were lost to follow-up 
during the study: 1 with family history of sudden death, asymptomatic, with normal ECG 
who was referred for comprehensive evaluation for potentially inherited cardiac conditions; 
1 with infero-lateral T-wave inversion; and 1 with inferior T-wave inversion. 
 
Cost of screening program and further investigations: 
The cardiac screening program was organised and supported by Cardiac Risk in the Young 
(CRY) at a nominal rate of £35 per player. This included initial evaluation with health 
questionnaire, 12-lead ECG, consultation with a cardiologist and on-site TTE as required. 
Thus the cost of initial screening for all 1191 rugby players was £41,685. All further 
evaluations were performed after referral by the relevant player’s family physician to a 
specialist cardiac centre via the NHS. Cost estimates for the referrals and further tests were 
based on published NHS payment-by-result tariffs as follows: cardiology consultation (£210), 
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TTE (£57), 24-hour ECG (£145) and ETT (£145), CMR with reporting (£229), and catheter 
ablation (£2164). The cost of all these additional tests and follow-up was £18,190. The total 
cost for the 1191 athletes was £59875, averaging a cost of approximately £50 per player 
screened. A total of 7 players were identified with an abnormality; of these 2 had serious 
and potentially life-threatening cardiac disease (1 HCM, 1 WPW) and another 5 needed 
long-term surveillance. Thus the cost of identifying a player with any cardiac abnormality 
was £8,554, while the cost of identifying one player with potentially life-threatening 
condition was £29,938. 
 
Assuming an ECG sensitivity of 100% for potentially life-threatening conditions, the false 
positive rate for the screening program comprised of health questionnaire, ECG and 
consultation was 9.5%, the majority (96 of the 115 cases) comprised of a false positive ECG. 
The inclusion of selective on-site TTE reduced the false positive rate to 2.7% by clearing 81 
cases that would otherwise require referral to a cardiology specialist for further evaluation. 
That would equate to overall savings of £21,627 (£18 per athlete screened) assuming that 
every individual referred to a specialist would require as a minimum a cardiology 
consultation and a TTE as part of their evaluation. 
 
Evaluation of different ECG screening criteria: 
Utilising the 2010 ESC ECG criteria would have increased the ECG false positive rate from 
8.8% to 20.1%, due to the inclusion of a considerable number of athletes outside the 
conservative QTc intervals (n=58 with QTc <380ms; n=53 with QTc >440ms) and the 
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presence of a PR interval < 120ms in the absence of pre-excitation (n=23).4 Assuming that all 
individuals would require as a minimum on further evaluation, a cardiology consultation, a 
24-hour ECG and ETT, the estimated additional costs would amount to a minimum of 
£67,000 for the entire cohort or £56 per athlete screened. 
 
Utilising the Seattle criteria would have resulted in an overall reduction of the ECG false 
positive rate from 8.8% to 6.5%.5 The reduction in the false positive rate would be primarily 
due to differences in the definition of T-wave inversion requiring further evaluation in the 
anterior (n=8 confined in V1-V2) and inferior (n=15 in leads III and aVF only). In addition, 11 
athletes would not require TTE based on the Seattle definitions of RVH (n=5) and non-
specific Intraventricular conduction delay (n=1) and the exclusion of RBBB (n=5) from ECG 
anomalies indicative of cardiac pathology. On the contrary, based on the Seattle criteria 
definition of pathological Q-waves, 7 additional athletes would have required at least on-
site TTE. 
 
Utilising the refined ECG criteria as proposed by Sheikh et al.8 would result in significant 
reduction of the false positive ECG rate from 8.8% to 4.9%. This is due to the inclusion of 
ECG criteria for atrial enlargement, QRS axis deviation and right ventricular hypertrophy, 
when present in isolation, to normal variants (Table 3). Such criteria were present in 
isolation in 49 athletes. Only 1 athlete with isolated right axis deviation (RAD) demonstrated 
evidence of mild pulmonary stenosis on TTE, requiring regular surveillance. 
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DISCUSSION: 
Concerns relating to the implementation of pre-participation cardiac screening in 
competitive athletes focus primarily on the low incidence of SCD in young athletes, the 
associated high false positive rates and prohibitive costs. Published literature relating to the 
impact and cost-effectiveness of cardiac screening in athletes reports highly variable results, 
in a non-standardised way, and is commonly based on a number of assumptions and 
theoretical projections. This is the first large-scale study to report on a real life, nationwide 
screening program of elite competitive athletes from a single sporting discipline. 
Importantly, this study involves a cohort of professional athletes of extraordinary size and 
strength often considered likely to exhibit a higher prevalence of ECG anomalies and 
extremes of cardiac dimensions, posing a greater challenge in differentiating athlete’s heart 
from quiescent cardiac disease. 
 
Value of individual screening modalities: 
In our study, both rugby players with potentially life threatening cardiac abnormalities (HCM 
and WPW) were detected on the basis of an abnormal ECG. Reassuringly, the ECG would 
have flagged both players for further evaluation, irrespective of the criteria used. In 
addition, the ECG prompted further evaluation with TTE in 3 other players with less 
significant cardiac abnormalities: 1 with RBBB and bi-cuspid aortic valve, 1 with isolated RAD 
and mild pulmonary stenosis and 1 with inferior T-wave inversion and PDA. It is unclear 
whether these ECG anomalies relate to the structural findings or are simply a chance 
finding. 
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On the contrary, of the 179 (15%) athletes who reported cardiovascular symptoms on the 
questionnaire, only 0.5% were considered significant after consultation with our 
cardiologist. This highlights the importance of employing physicians with experience is the 
field of sports cardiology and inherited cardiac diseases, who are able to distinguish benign 
symptoms from those indicative of cardiac pathology. None of the players with symptoms 
demonstrated any significant abnormality on further investigations or follow-up. Similar to 
existing studies, our study underscores the poor predictive value of symptoms as indicators 
of cardiac disease in young athletes and reinforces the importance of ECG for the detection 
of cardiac conditions implicated in SCD.11-14 
 
Utility of different ECG criteria: 
Our study demonstrated a false positive ECG rate of 8.8% utilising our group’s criteria, which 
are similar to the criteria proposed by the ESC in 2010 with notable exception the definitions 
of an abnormal QT interval and pre-excitation. This is very reassuring given the athletic 
prowess and body habitus of our athletes, as it compares favourably with the false positive 
rates reported in the literature. Although direct comparisons are difficult due to the 
different ECG criteria used, our results are similar to the study by Chevalier et al., who 
evaluated 135, predominantly Caucasian, French, rugby players and identified distinctly 
abnormal ECGs, comprised of T-wave inversions, extreme axis deviation and pre-excitation, 
in 4% of the players.15 
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It is widely accepted that the criteria recommended by the ESC for the interpretation of a 
young athlete’s ECG require refinement in order to incorporate data that have emerged 
since 2010 and to accommodate for the effect of ethnicity, age, gender and sporting 
discipline on the athlete’s ECG.16-21 The Seattle criteria, published in 2013, were an 
improvement on the ESC criteria resulting in significant reduction of the false positive 
results and therefore a reduction of athletes subjected to unnecessary and costly 
investigations. Recent publications, however, investigated a number of ECG indices, 
considered by both expert consensus documents to represent phenotypes of quiescent 
cardiac pathology, and demonstrated that in isolation they were unlikely to be associated 
with disease.22,23 This led to a proposal for further refinement of the ECG criteria in athletes, 
which on initial assessment appear to reduce the number of false positive tests and improve 
specificity without compromising the sensitivity of the ECG in detecting potentially sinister 
cardiac disease.8,24 In agreement with current literature, the adoption of the 2010 ESC 
criteria in our cohort would have resulted in an unacceptably high proportion (20%) of 
athletes requiring further evaluation with escalating costs but no apparent increase in the 
diagnostic yield. In contrast application of the Seattle or the refined criteria would have 
reduced the false positive rate to 6.5% and 5%, respectively, while still identifying the two 
athletes with potentially life threatening conditions.8,24,25 
 
Cost-effectiveness of cardiac screening: 
Literature on the cost-effectiveness of cardiac screening is fairly limited and suggests highly 
variable costs ranging from $42,900 per life-year saved to $14.4 million per life saved. These 
results should be viewed with caution as all existing studies exhibit significant limitations. 
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First and foremost all studies use theoretical projection models rather than true costs. 
Secondly, Wheeler et al.26 and Halkin et al.27 extrapolated results from the Italian experience 
to the US population, predominantly high-school athletes, which may not hold true. Finally, 
the studies by Wheeler et al.26 and Fuller et al.28 include a number of arbitrary assumptions 
relating to the life years saved by identifying a potentially life-threatening condition. Our 
study is the first study to report on a real life, nationwide screening programme of elite, 
professional athletes competing in a single sporting discipline. The cost of £50 per player or 
£29,938 ($44,668 or €41,000 based on exchange rates on the 01/04/2015) per condition 
identified is well within the conventional cost-effectiveness limits utilised in different health 
care systems, even if we assume that only 1 life-year was saved for every condition 
identified. 
 
There is general consensus that routine TTE is not recommended as part of the initial 
athlete’s evaluation, as it only improves marginally the diagnostic yield for conditions 
predisposing to SCD in young athletes at a high cost.28,29 This would have also been true for 
the CRY screening programme as performing a TTE in every player would have considerably 
reduced the number of players screened per session and would have had a significant 
impact on our resources and associated costs. Our model, however, introduces a novel 
screening protocol, which utilises on-site TTE as a second line investigation. In our cohort 
only 1 in 10 rugby players required a TTE. The addition of on-site TTE reduced the athletes 
requiring further evaluation from 9.7% to 2.9%, resulting in considerable savings (£10,814 
per potentially life-threatening condition identified and £18 per athlete screened) and 
minimising the burden and costs of further comprehensive evaluation on the NHS. In 
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addition, excluding a severe disease phenotype on TTE offers considerable reassurance to 
the player, team and physician until further investigations are completed. 
 
Finally, the adoption of more refined ECG criteria is likely to result in considerable cost 
savings as our study indicates that they may potentially reduce the ECG false positive rate to 
less than 5%. Such a low false positive rate may negate the need for on-site TTE in our 
programme or at the very least reduce the burden of TTE as only 1 in every 20 athletes will 
fail initial evaluation. 
 
Limitations: 
The lack, of a specific pathway for further evaluation after the initial screening and reliance 
on primary care physicians to initiate an NHS referral to a centre of their choice meant that 
athletes with similar phenotypes were investigated in a variable way. In addition, for a 
significant proportion of the athletes, the authors relied on reports from other centres, 
though specialist, rather than our own investigative outcomes. 
 
The reported costs were subsidised by the charitable organisation CRY and as such it may be 
argued that they underestimate the true cost of screening. If we substitute the CRY fee of 
£35 for the cost of a cardiology consultation and 12-lead ECG (£210) that the NHS charges 
then the cost per condition identified would raise to £134,150 and the cost per athlete 
screened to £225. However, the aim of the study was to present a real life, sustainable 
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screening program. Cardiac risk in the young is a well-established charity in existence since 
1995. Since its inception the screening program has expanded year upon year, and the 
charity currently screens in excess of 17,000 young individuals per annum with the exact 
screening protocol described in this study. As such, although the costs associated with 
screening young athletes may seem unattainable for the strained financial resources of 
many health care systems, our study provides at the very least a convincing argument for 
alternative funding sources that national health care systems and sporting organisations 
should consider. 
 
Conclusion: 
Our study on a well-characterised cohort of elite professional athletes demonstrates that 
cardiac screening with 12-lead ECG is feasible and may result in the identification of 
potentially sinister conditions. The refinement of the ECG criteria and the expert setting 
safeguard a relatively low false positive rate, minimise the burden of unnecessary 
investigations and reduce costs. 
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What is already known on this subject 
 Sudden cardiac death is one of the leading causes of death in young (≤35 years) 
athletes. 
 ECG-based cardiac screening of athletes can identify conditions predisposing to 
sudden cardiac death. 
 Widespread implementation of cardiac screening in competitive athletes is hindered 
by concerns relating to the low incidence of SCD in young athletes, the high false 
positive rate of the 12-lead ECG and prohibitive costs of subsequent investigations. 
What this study adds 
 Nationwide cardiac screening with 12-lead ECG is feasible and can identify 
potentially sinister conditions. 
 Adoption of refined ECG criteria and the expert setting safeguard a relatively low 
false positive rate, minimise the burden of unnecessary investigations and reduce 
costs. 
 On-site, second line echocardiography reduces referral rates for further 
investigations and may limit costs. 
 Although the costs associated with screening young athletes may seem unattainable 
for the strained financial resources of most national health care systems, screening 
could be implemented by utilising alternative funding sources such as sporting 
federations, clubs and charitable organisations. 
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TABLES 
 
Table 1: ECG criteria considered abnormal during CRY screenings leading to further 
evaluation. Comparison is presented with the 2010 ESC criteria and the 2013 Seattle 
criteria. 
ECG Abnormality ESC Recommendation Seattle 
Recommendation 
CRY ECG criteria 
Right atrial enlargement P-wave amplitude ≥ 
2.5mm in lead II, III, or 
aVF 
As ESC As ESC 
Left atrial enlargement Negative portion of the 
P wave in lead V1 ≥ 
1mm in depth and ≥ 
40ms in duration. 
Prolonged P wave 
duration of > 120ms in 
lead I or II with negative 
portion of the P wave ≥ 
1mm in depth and ≥ 
40ms in duration in 
lead V1 
As ESC 
Right QRS axis deviation >115° >120° As ESC 
Left QRS axis deviation −30° to −90° As ESC As ESC 
Right ventricular 
hypertrophy 
Sum of R wave in V1 
and S wave in V5 or V6 
≥ 10.5mm 
 
Sum of R wave in V1 
and S wave in V5 > 
10.5mm and right axis 
deviation > 120° 
As ESC 
Complete LBBB QRS ≥ 120ms, 
predominantly 
negative QRS complex 
in lead V1 (QS or rS), 
and upright 
monophasic R wave in 
leads I and V6 
As ESC As ESC 
Complete RBBB RSR′ pattern in 
anterior precordial 
Not relevant As ESC 
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leads with QRS 
duration ≥120 ms 
Non-specific 
Intraventricular 
conduction delay 
Any QRS duration > 
110ms of non RBBB or 
LBBB morphology 
Any QRS duration ≥ 
140ms 
Any QRS duration ≥ 
120ms of non RBBB or 
LBBB morphology 
Pathological Q-wave > 4mm deep in any 
lead except III, aVR 
> 3mm deep or > 40ms 
duration in ≥ 2 leads 
except III and aVR 
≥ 40ms in duration or ≥ 
25% of the height of the 
ensuing R wave 
Significant T-wave 
inversion 
≥ 2mm in ≥ 2 adjacent 
leads (deep) or 
“minor” in ≥ 2 leads 
> 1mm in depth in ≥ 2 
leads V2−V6, II and aVF, 
or I and aVL (excludes 
III, aVR, and V1) 
≥ 1mm deep in ≥ 2 
adjacent leads  
ST-segment depression ≥ 0.5mm deep in ≥ 2 
leads 
 
As ESC As ESC 
Ventricular pre-
excitation 
PR interval < 120ms 
with or without delta 
wave 
PR interval < 120ms 
with delta wave 
PR interval < 120ms 
with delta wave 
Atrial arrhythmias Not stated Supraventricular 
tachycardia, atrial-
fibrillation, atrial-flutter 
Supraventricular 
tachycardia, atrial-
fibrillation, atrial-flutter 
Ventricular arrhythmias Not stated ≥2 PVCs per 10sec 
tracing and couplets, 
triplets and non-
sustained ventricular 
tachycardia 
≥1 PVC per 10sec 
tracing and any other 
ventricular arrhythmias 
Prolonged QTc > 440ms ≥ 470ms ≥ 470ms 
Short QTc < 380ms ≤ 320ms ≤ 320ms 
Brugada-like pattern Brugada-like early 
repolarisation pattern 
High take-off and 
downsloping ST 
segment elevation 
followed by a negative 
T wave in ≥2 leads in 
V1–V3 
Type-1 pattern OR type-
2 that converts to type-
1 by raising leads V1 
and V2 to 3rd and 2nd 
intercostal space 
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Table 2: Demographic characteristics of rugby players 
 
  
Mean ± SD 
 
Age (years) 
 
 
22.5 ± 5.1 
 
Height (cm) 
 
 
185.4 ± 7.3 
 
Weight (kg) 
 
 
99.1 ± 12.8 
 
Body Mass Index (kg/m2) 
 
 
28.8 ± 3.1 
 
Body Surface Area (m2) 
 
 
2.25 ± 0.2 
  
 
ETHNICITIES 
 
 
Percentage 
 
Caucasian 
 
 
1019 (85.6%) 
 
Afro-Caribbean 
 
 
66 (5.5%) 
 
Other* 
 
 
106 (8.9%) 
  
(*) = Players from Argentina, New Zealand, Pacific Islands and South Africa 
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Table 3: ECG characteristics of rugby players 
 
ECG Parameter 
Numbers (%) 
n=1191 
GROUP 1 (training-related) ECG findings  
Sinus Bradycardia (HR < 60) 507 (42.6%) 
1st Degree AV Block (PR > 120ms) 99 (8.3%) 
Partial Right Bundle Branch Block 92 (7.7%) 
Left Ventricular Hypertrophy 275 (23.1%) 
Early Repolarization – overall prevalence 
- ER in anterior leads 
- ER in inferior and/or lateral leads 
578 (48.5%) 
468 (39.9%) 
244 (20.5%) 
GROUP 2 (training-unrelated) ECG findings  
Abnormal T-wave inversions (TWI) 
- TWI confined in anterior leads 
- TWI in inferior leads 
- TWI in lateral leads 
42 (3.5%) 
12 (1%) 
27 (2.3%) 
3 (0.25%) 
Abnormal Q-waves 1 (0.08%) 
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Right Bundle Branch Block 7 (0.6%) 
Left Bundle Branch Block 1 (0.08%) 
Right Atrial enlargement 
4 (0.3%) 
[3 in isolation] 
Left Atrial Enlargement 
9 (0.8%) 
[7 in isolation] 
Right Axis Deviation 
13 (1.1%) 
[10 in isolation] 
Left Axis Deviation 
31 (2.6%) 
[24 in isolation] 
Right Ventricular Hypertrophy 
12 (1%) 
[5 in isolation] 
Ventricular Ectopics 6 (0.5%) 
2nd Degree (Wenckebach) AV Block 1 (0.08%) 
Inter-ventricular Conduction Delay 1 (0.08%) 
Wolff-Parkinson-White pattern 1 (0.08%) 
Prolonged QTc interval (≥ 470ms) 3 (0.25%) 
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Brugada pattern 0 
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FIGURES 
Figure 1: Prevalence of ECG abnormalities in rugby players according to ESC classification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33%
58%
9%
ECG changes in rugby players
Normal
Group 1 ECG
Group 2 ECG
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Figure 2: Flow chart of preparticipation screening of 1191 elite rugby players 
 
 
 
* Dilated left ventricular cavity (n=3), T-wave inversions in anterior and lateral leads (n=1), 
bicuspid aortic valve (n=1), mild mitral regurgitation (n=1), mild pulmonary stenosis (n=1), 
mildly dilated aortic root (n=1), patent ductus arteriosus (n=1). 
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Figure 3: ECG of athletes with major cardiac abnormality; (a) ECG showing T-wave 
inversions in athlete with HCM; (b) Pre-excitation and delta wave suggestive of WPW 
syndrome 
 
 
 
HCM, Hypertrophic Cardiomyopathy; WPW, Wolff-Parkinson-White 
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